Theravance Biopharma, Inc.
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $107.5M
- Net income
- $105.9M
- Total assets
- $485.6M
- Market cap
- $839.8M
- Operating margin
- -3.4%
- Net margin
- 98.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $107.5M
- Operating expenses
- $111.1M
- Operating income
- -$3.6M
- Income tax
- $23.4M
- Net income
- $105.9M
- EPS (basic)
- $2.10
- EPS (diluted)
- $2.06
Balance sheet
- Total assets
- $485.6M
- Current assets
- $418.5M
- Total liabilities
- $188.8M
- Current liabilities
- $38.3M
- Shareholders’ equity
- $296.7M
Cash flow
- Operating cash flow
- $238.5M
- Investing cash flow
- -$105.3M
- Financing cash flow
- -$3.2M
- Net cash flow
- $130.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $839.8M
- P/E ratio
- 7.9
- EPS (diluted)
- $2.06
- Shares outstanding
- 51.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 16, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $105.9M in FY2025.
- Revenue grew 94% from FY2021 to FY2025.
- Trading 21% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 7.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Theravance Biopharma, Inc..
Write a review
News about Theravance Biopharma, Inc.
News & sentiment via Polygon.io
